Clinical Outcome of Alloantibody in Thalassemia Patient
Abstract
Background: Thalassemia is a common hemoglobin ailment in Bangladesh and one of the major public health complications. Although blood transfusions are lifesavers for thalassemia patients, they may be associated with some complications especially erythrocyte alloimmunization. The development of alloantibodies may complicate the management of patients with thalassemia. An extended antigenic matching may decrease the risk of alloimmunization.
Objective: The aim of the study was to evaluate the outcome of alloantibody in thalassemia patient.
Methods: This is an observational study. This study was carried out on 105 population including male and female patients in the Department of Transfusion Medicine, Bangabandhu Sheikh Mujib Medical University, Chittagong Medical College Hospital and MH Samorita Hospital & Medical College, Bangladesh. The duration of the period from January 2022 to December 2022. The period from Data was entered in MS Excel and Statistical analysis was done using SPSS-24.
Results: The total study population was 105 patients aged 10 – 30 years, 49(46.67%) were ≤10 years, 19(18.09%) were 11-19 years, 20(19.04%) were 20-29 years and 17(16.19%) were ≥30years. And sex distribution of the population where, 28(26.66%) were male and 77(73.33%) were Female.
Conclusion: Thalassemia patients may benefit from receiving red blood cells (RBC) transfusions based on extended antigen matching as demonstrated by the lack of new alloantibodies. There is relatively high rate of alloimmunization in the patients and red cell alloimmunization should not be overlooked in patients receiving regular blood transfusions.
Downloads
References
Aster JC. Red blood cell and bleeding disorders. Robbins and Cotran pathologic basis of disease. 7th ed. Pennsylvania: Elsevier Saunders. 2005:632.
Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, Daluei MK. Alloimmunization among transfusion-dependent thalassemia patients. Asian journal of transfusion science. 2009 Jul;3(2):95.
Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences. 1998 Jun;850(1):251-69.
Modell B, Khan M, Darlison M, King A, Layton M, Old J, Petrou M, Varnavides L. A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bulletin of the World Health Organization. 2001;79(11):1006-13.
Rajab A, Patton MA. Major factors determining the frequencies of hemoglobinopathies in Oman. American journal of medical genetics. 1997 Aug 1;71(2):240-2.
Lukens JN. The thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. Wintrobe's clinical hematology. 1993;1103.
Rebulla PJ. Blood transfusion in beta thalassaemia major. Transfusion Medicine. 1995 Dec;5(4):247-58.
Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox sanguinis. 2000;79(3):129-37.
The aim of this descriptive study is to provide frequency and distribution patterns of various types of irregular red cell alloantibodies in patients with thalassemia major at two centers.
Bilwani, F., Nabi, G., Adil, S., Usman, M., Hassan, F. and Khurshid, M., 2005. Frequency of irregular red cell alloantibodies in patients with thalassemia major: a bicenter study. Journal of Pakistan Medical Association, 55(12), p.563.
Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, The Journal of the American Society of Hematology. 2000 Nov 15;96(10):3369-73.
Sirchia G, Zanella A, Parravicini A, Rebulla P, Morelati F, Masera G. Red cell alloantibodies in thalassemia major: results of an Italian cooperative study. Transfusion. 1985 Mar 4;25(2):110-2.
Spanos TH, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox sanguinis. 1990 Jan;58(1):50-5.
Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long‐term red cell transfusion in transfusion‐dependent thalassemia patients. Transfusion. 2005 May;45(5):761-5.
28. Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and next-generation sequencing. Transfusion medicine reviews. 2014 Oct 1;28(4):177-86.
Chen C, Tan J, Wang L, Han B, Sun W, Zhao L, Huang C, Tan B, Qin L. Unexpected red blood cell antibody distributions in C hinese people by a systematic literature review. Transfusion. 2016 Apr;56(4):975-9.
Kay B, Poisson JL, Tuma CW, Shulman IA. Anti‐Jka that are detected by solid‐phase red blood cell adherence but missed by gel testing can cause hemolytic transfusion reactions. Transfusion. 2016 Dec;56(12):2973-9.
Castro O, Sandler SG, Houston‐Yu P, Rana S. Predicting the effect of transfusing only phenotype‐matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion. 2002 Jun;42(6):684-90.
Ribeiro KR, Guarnieri MH, Da Costa DC, Costa FF, Pellegrino Jr J, Castilho L. DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen‐matched blood in patients with sickle cell disease. Vox sanguinis. 2009 Aug;97(2):147
Castilho L, Rios M, Pellegrino Jr J, TO Saad S, F. Costa F. Blood group genotyping facilitates transfusion of β‐thalassemia patients. Journal of clinical laboratory analysis. 2002;16(5):216-20.
Guelsin GA, Sell AM, Castilho L, Masaki VL, Melo FC, Hashimoto MN, Higa TT, Hirle LS, Visentainer JE. Benefits of blood group genotyping in multi‐transfused patients from the south of Brazil. Journal of clinical laboratory analysis. 2010;24(5):311-6.
Bhatti FA, Salamat N, Nadeem A, Shabbir N. Red cell immunization in beta thalassaemia major. Journal of the College of Physicians and Surgeons--pakistan: JCPSP. 2004 Nov 1;14(11):657-60.
Salama MA, Sadek NA, Hassab HM, Abadeer AF, Mikhael IL. Erythrocyte autoantibodies and expression of CD59 on the surface of red blood cells of polytransfused patients with ß-thalassaemia major. British journal of biomedical science. 2004 Jan 1;61(2):88-92.
Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, The Journal of the American Society of Hematology. 2000 Nov 15;96(10):3369-73.
Sirchia G, Zanella A, Parravicini A, Rebulla P, Morelati F, Masera G. Red cell alloantibodies in thalassemia major: results of an Italian cooperative study. Transfusion. 1985 Mar 4;25(2):110-2.
Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, Daluei MK. Alloimmunization among transfusion-dependent thalassemia patients. Asian journal of transfusion science. 2009 Jul;3(2):95.
Cheng CK, Lee CK, Lin CK. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion. 2012 Oct;52(10):2220-4.
Bhatti FA, Salamat N, Nadeem A, Shabbir N. Red cell immunization in beta thalassaemia major. Journal of the College of Physicians and Surgeons--pakistan: JCPSP. 2004 Nov 1;14(11):657-60.
Ameen R, Al‐Shemmari S, Al‐Humood S, Chowdhury RI, Al‐Eyaadi O, Al‐Bashir A. RBC alloimmunization and autoimmunization among transfusion‐dependent Arab thalassemia patients. Transfusion. 2003 Nov;43(11):1604-10.
